Published online Mar 14, 2020. doi: 10.3748/wjg.v26.i10.1029
Peer-review started: November 21, 2019
First decision: January 7, 2020
Revised: February 15, 2020
Accepted: February 21, 2020
Article in press: February 21, 2020
Published online: March 14, 2020
Processing time: 114 Days and 6.1 Hours
Nonalcoholic fatty liver disease (NAFLD) is a global metabolism-associated liver disease. Hepatic steatosis, inflammation, and insulin resistance are the primary pathologic changes of NAFLD. Although NAFLD has become a serious threat to human public health, its pathogenic mechanisms are largely unknown.
Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a newly discovered conserved neurotrophic factor. Recent studies found that MANF is involved in diabetes, obesity, and metabolic homeostasis. However, much remains to be discovered about its function in hepatic lipid metabolism; thus, we detected whether MANF could regulate hepatic metabolism.
This study aimed to detect MANF expression in both in vivo and in vitro NAFLD models and explore the role of MANF in hepatic lipid metabolism.
HepG2 cells treated with free fatty acids and ob/ob mice were used as NAFLD models. Liver tissues collected from WT and ob/ob mice were used to detect MANF expression. Cells were treated with free fatty acids for different durations. Moreover, we established overexpression and knockdown cell models with lentiviruses to interfere with MANF expression levels in order to observe whether MANF influences hepatic steatosis.
Hepatic MANF expression was obviously decreased in ob/ob mice compared with wild type mice. The MANF level was elevated temporarily and gradually decreased in HepG2 cells as the duration of treatment with high free fatty acids increased. MANF deficiency accelerated lipogenesis and aggravated HepG2 cell steatosis, while MANF overexpression inhibited lipogenesis and rescued HepG2 cells from free fatty acids-induced steatosis.
MANF alleviated lipid deposition and suppressed lipogenes, showing a potential protective role in NAFLD.
MANF may be a potential therapeutic target in hepatic steatosis processes.